Pfizer (NYSE:PFE) Trading Up 2.6% – Here’s Why

Shares of Pfizer Inc. (NYSE:PFE) shot up 2.6% during trading on Monday . The company traded as high as $27.82 and last traded at $27.7510. 45,805,413 shares were traded during trading, a decline of 0% from the average session volume of 45,827,262 shares. The stock had previously closed at $27.04.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Belgian court ordered Poland and Romania to buy about €1.9 billion ($2.2B) of Pfizer COVID-19 vaccines, which reduces contract uncertainty and could bring near‑term revenue recognition. Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines
• Positive Sentiment: Technicals look constructive: PFE has traded above its 50- and 200-day simple moving averages for months and is up year-to‑date, signaling sustained investor confidence and supporting upside momentum. PFE Stock Trades Above 200 & 50-Day SMA for 3 Months: How to Play
• Positive Sentiment: Market commentary highlights recent oncology wins and pipeline bets as the main drivers of optimism for Pfizer’s growth prospects, which can support valuation despite a flat near‑term corporate outlook. Pfizer Stock Edges Higher as Oncology Wins and Pipeline Bets Fuel Optimism Amid Flat 2026 Outlook
• Neutral Sentiment: GSK and Shionogi reshaped ViiV Healthcare ownership as Pfizer exits the HIV joint venture; this reduces Pfizer’s participation in that franchise and simplifies its portfolio—impact is strategic but limited to near-term earnings. GSK and Shionogi Reshape ViiV Healthcare Ownership as Pfizer Exits HIV Venture
• Neutral Sentiment: Pfizer posted an update from a Swedish real‑world Ibrance study; fresh real‑world data can support label value and prescribing but the immediate market impact is uncertain until topline effects are shown. Pfizer’s Swedish Ibrance Study: Fresh Real‑World Data Signal for PFE Investors
• Negative Sentiment: Pfizer and BioNTech halted recruitment for a large U.S. trial of their updated COVID vaccine in adults 50–64 because enrollment was too low to generate usable data—this signals waning demand for next‑gen COVID shots and could weigh on future COVID vaccine revenue expectations. Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles
• Negative Sentiment: Reports that Pfizer will close its South San Francisco research site point to R&D consolidation; while that can reduce costs, it may also signal lower near‑term discovery throughput and can be viewed negatively by some investors. Pfizer close South San Francisco research site

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on PFE. Wolfe Research set a $24.00 target price on shares of Pfizer and gave the stock an “underperform” rating in a research report on Wednesday, December 17th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of Pfizer in a research note on Monday, March 9th. Royal Bank Of Canada began coverage on shares of Pfizer in a research report on Tuesday, February 24th. They set an “underperform” rating and a $25.00 price objective on the stock. TD Cowen restated a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. Finally, Citigroup initiated coverage on Pfizer in a research report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, Pfizer presently has an average rating of “Hold” and an average price target of $28.19.

Pfizer Price Performance

The stock has a market capitalization of $162.41 billion, a PE ratio of 21.00 and a beta of 0.47. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. The stock’s 50-day moving average is $26.94 and its 200 day moving average is $25.75.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. During the same quarter last year, the business posted $0.63 EPS. The company’s revenue for the quarter was down 1.2% on a year-over-year basis. As a group, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Stance Capital LLC raised its position in Pfizer by 26,746.0% during the fourth quarter. Stance Capital LLC now owns 26,846 shares of the biopharmaceutical company’s stock valued at $668,000 after acquiring an additional 26,746 shares in the last quarter. Rockefeller Capital Management L.P. grew its position in Pfizer by 27.1% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,842,275 shares of the biopharmaceutical company’s stock worth $45,873,000 after acquiring an additional 392,913 shares in the last quarter. World Investment Advisors increased its stake in shares of Pfizer by 11.2% during the 4th quarter. World Investment Advisors now owns 397,952 shares of the biopharmaceutical company’s stock worth $9,909,000 after purchasing an additional 40,239 shares during the last quarter. Nalls Sherbakoff Group LLC bought a new position in shares of Pfizer during the 4th quarter valued at $92,000. Finally, DUTCH ASSET Corp bought a new position in shares of Pfizer during the 4th quarter valued at $237,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.